RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Seth Y. Ablordeppey to Receptors, Dopamine D2

This is a "connection" page, showing publications Seth Y. Ablordeppey has written about Receptors, Dopamine D2.
Connection Strength

2.856
  1. Onyameh EK, Bricker BA, Eyunni SVK, Voshavar C, Gonela UM, Ofori E, Jenkins A, Ablordeppey SY. A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice? Bioorg Med Chem. 2021 01 15; 30:115943.
    View in: PubMed
    Score: 0.728
  2. Etukala JR, Zhu XY, Eyunni SV, Onyameh EK, Ofori E, Bricker BA, Kang HJ, Huang XP, Roth BL, Ablordeppey SY. Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem. 2016 08 15; 24(16):3671-9.
    View in: PubMed
    Score: 0.532
  3. Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 01; 24(17):4294-7.
    View in: PubMed
    Score: 0.467
  4. Sampson D, Zhu XY, Eyunni SV, Etukala JR, Ofori E, Bricker B, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Identification of a new selective dopamine D4 receptor ligand. Bioorg Med Chem. 2014 Jun 15; 22(12):3105-14.
    View in: PubMed
    Score: 0.459
  5. Sikazwe DM, Nkansah NT, Altundas R, Zhu XY, Roth BL, Setola V, Ablordeppey SY. Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups. Bioorg Med Chem. 2009 Feb 15; 17(4):1716-23.
    View in: PubMed
    Score: 0.318
  6. Sikazwe DM, Li S, Mardenborough L, Cody V, Roth BL, Ablordeppey SY. Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors. Bioorg Med Chem Lett. 2004 Dec 06; 14(23):5739-42.
    View in: PubMed
    Score: 0.240
  7. Lyles-Eggleston M, Altundas R, Xia J, Sikazwe DM, Fan P, Yang Q, Li S, Zhang W, Zhu X, Schmidt AW, Vanase-Frawley M, Shrihkande A, Villalobos A, Borne RF, Ablordeppey SY. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J Med Chem. 2004 Jan 29; 47(3):497-508.
    View in: PubMed
    Score: 0.057
  8. Sikazwe DM, Li S, Lyles-Eggleston M, Ablordeppey SY. The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 03; 13(21):3779-82.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support